●Clinical translation of angiogenesis inhibitors. Kerbel, R. & Folkman, J. Nature Reviews Cancer October (2002) Kerbel and Folkman highlight how the successful development of drugs that target tumour angiogenesis could be greatly facilitated by the transfer of expertise from scientists who are familiar with the biology of angiogenesis to clinicians.

●Genes and patent policy: rethinking intellectual property rights. Andrews, L. B. Nature Reviews Genetics October (2002) Andrews discusses the various policy options that are being explored to ensure that gene patents do not impede the practice of medicine and the evolution of science.

●Furin at the cutting edge: from protein traffic to embryogenesis and disease. Thomas, G. Nature Reviews Molecular Cell Biology October (2002)

●Inflammation takes on Alzheimer disease. Golde, T. E. Nature Medicine September (2002) This News and Views article discusses the therapeutic implications of new data that indicate that the inflammatory response due to the accumulation of amyloid-β in the brains of people with Alzheimer's disease might not always be harmful.

●Ligand-targeted therapeutics in anticancer therapy. Allen, T. M. Nature Reviews Cancer October (2002)

●Transcription factors as targets for cancer therapy. Darnell, J. E. Nature Reviews Cancer October (2002)

●NF-κB regulation in the immune system. Li, Q. & Verma, I. M. Nature Reviews Immunology October (2002) Recent developments in our understanding of how NF-κB signalling is controlled might allow new anti-inflammatory drugs to be developed.

●Gene silencing in mammals by siRNAs. McManus, M. T. & Sharp, P. A. Nature Reviews Genetics October (2002)

●Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Schenk, D. Nature Reviews Neuroscience October (2002)